A new clinical trial is looking to test the benefits of matching a tumor’s molecular profile to targeted agents in patients with advanced solid tumors or lymphomas.
Enrollment is now open for the pioneering precision medicine clinical trial known as the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH). Approximately 1,000 patients with advanced solid tumors or lymphomas that have not responded to standard therapy may find new treatment options through this study.
This phase II, interventional trial is enrolling patients at clinical sites participating in the NCI’s National Clinical Trials Network (NCTN), including Cleveland Clinic.
In this trial – the largest precision oncology trial ever launched, according to the National Cancer Institute – researchers will analyze each patient’s tumor for the presence of genomic abnormalities for which a targeted drug exists. If a match is found, treatment may be assigned.
“This trial is a well-designed attempt to determine whether cancers can be treated according to their molecular profiles, following the premise of personalized medicine,” says Petros Grivas, MD, PhD, of Cleveland Clinic’s Department of Hematology and Medical Oncology. Dr. Grivas is a national Principal Investigator for one of the trial’s 20 treatment arms, and thus is helping to develop a treatment subprotocol.
The phase II interventional trial, known as the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), is enrolling patients at as many as 2,400 clinical sites that participate in the NCI’s National Clinical Trials Network (NCTN). Cleveland Clinic is working to activate the trial as soon as it becomes available as a member of that network.